Thomas Hanke

Thomas Hanke

SGC Frankfurt

Hanke

Thomas Hanke

+49 (0)69 798-29313

Affiliations

Biography

Thomas Hanke studied Pharmacy at the Goethe University in Frankfurt. In 2014, he completed his PhD in the field of pharmaceutical chemistry, investigating the synthesis and pharmacological characterization of dual 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 inhibitors as a new alternative strategy for anti-inflammatory drugs. In 2015, he joined Stefan Knapp´s group where he is working on the development of chemical probes for targeting kinases. For that, he is pursuing different strategies, including the synthesis of allosteric kinase inhibitors (e.g. for LIMK1/2) and the synthesis of macrocyclic compounds to generate new chemistry for targeting kinases.

2017

Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement.

Vasta JD, Corona CR, Wilkinson J, Zimprich CA, Hartnett JR, Ingold MR, Zimmerman K, Machleidt T, Kirkland TA, Huwiler KG, Ohana RF, Slater M, Otto P, Cong M, Wells CI, Berger BT, Hanke T, Glas C, Ding K, Drewry DH, Huber KVM, Willson TM, Knapp S, Müller S, Meisenheimer PL, Fan F, Wood KV, Robers MB

Cell Chem Biol. 2017-11-13 . .doi: 10.1016/j.chembiol.2017.10.010

PMID: 29174542

Hyperactive locomotion in a Drosophila model is a functional readout for the synaptic abnormalities underlying fragile X syndrome.

Kashima R, Redmond PL, Ghatpande P, Roy S, Kornberg TB, Hanke T, Knapp S, Lagna G, Hata A

Sci Signal. 2017-5-2 . 10(477): .doi: 10.1126/scisignal.aai8133

PMID: 28465421